Compare ADMA Biologics Inc (ADMA) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Salesforce Inc — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Salesforce Inc trades at $166.36 (market cap $138.84B). The key difference: Salesforce Inc is far larger — about 65.2× ADMA Biologics Inc's market cap, and Salesforce Inc pays a 1.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CRM | |
|---|---|---|
Market Cap | $2.13B | $138.84B |
Sector | Health | Technology |
52-Week High | $20.38 | $273.65 |
52-Week Low | $7.60 | $150.12 |
Enterprise Value | $2.20B | $168.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Salesforce (CRM) trades at $166.59, up 0.57% today, with strong fundamentals including 77.64% gross margins and consistent earnings beats. The stock faces technical headwinds with mixed signals from moving averages and oscillators, while analyst consensus remains strongly bullish with a $235.20 price target. Recent news highlights AI-driven growth potential amid sector volatility.
Outlook: CRM's robust profitability and AI monetization (Agentforce ARR up 200% YoY per Seeking Alpha Apr 3) support upside, but near-term risks include software sector sell-offs and RSI overbought conditions. Valuation at 19.64 P/E offers room for growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
